Sort
64,565 grants matching “drug discovery”
Resolving ensemble averaged conformations by multi-temperature x-ray crystallography
$481,088James Solomon Fraser · University Of California, San Francisco · R01 · FY2018 · GM
Protease Activated Receptor Type 2 Targeting for Migraine Pain
$481,084Theodore J Price · University Of Texas Dallas · R01 · FY2019 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain
$481,084Theodore J Price · University Of Texas Dallas · R01 · FY2020 · NS
Protease Activated Receptor Type 2 Targeting for Migraine Pain
$481,084Theodore J Price · University Of Texas Dallas · R01 · FY2021 · NS
Identification of Gene Polymorphisms Associated with Infectious Diseases
$481,072Cheryl Winkler · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Data-driven drug discovery: investigating the molecular mechanisms of safety and efficacy
$481,069Nicholas P Tatonetti · Columbia University Health Sciences · R35 · FY2020 · GM
Data-driven drug discovery: investigating the molecular mechanisms of safety and efficacy
$481,069Nicholas P Tatonetti · Columbia University Health Sciences · R35 · FY2021 · GM
Data-driven drug discovery: investigating the molecular mechanisms of safety and efficacy
$481,069Nicholas P Tatonetti · Columbia University Health Sciences · R35 · FY2019 · GM
Natural feedstocks for diversity-oriented synthesis
$481,066Dennis L Wright · Promiliad Biopharma, Inc. · R42 · FY2007 · GM
Evidence-based Drug-Interaction Discovery: In-Vivo, In-Vitro and Clinical
$481,051Lang Li · Indiana University Indianapolis · R01 · FY2015 · LM
Computer Model of the Canine Ventricle
$481,040Robert F Gilmour · Cornell University · R01 · FY2006 · HL
Screening for inhibitors of NSD3 as a treatment for lung cancer
$481,033Jolanta Grembecka · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Human Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling
$481,020Joseph C Wu · Stanford University · R01 · FY2020 · HL
The development and validation of a novel tool for the assessment of bulbar dysfunction in ALS
$481,005Yana Yunusova · Sunnybrook Research Institute · R01 · FY2021 · DC
The development and validation of a novel tool for the assessment of bulbar dysfunction in ALS
$481,005Yana Yunusova · Sunnybrook Research Institute · R01 · FY2022 · DC
Eukaryotic transcriptome engineering via sequence-specific regulation of endogenous RNA
$481,000Patrick Hsu · Salk Institute For Biological Studies · DP5 · FY2018 · OD
Investigating the mechanisms that make jumbophages impervious to bacterial immune systems
$480,990Joseph Bondy-Denomy · University Of California, San Francisco · R01 · FY2022 · AI
Evaluating the Blood-Brain Barrier Bioavailability and in vivo Efficacy Potential of a Novel TAK1 Inhibitor Targeting Chronic Pain
$480,955Scott Scarneo · Eydis Bio, Inc. · R43 · FY2021 · NS
Engineering a Human Skeletal Muscle Tissue Model of LGMD2B
$480,947Nenad Bursac · Duke University · R01 · FY2025 · AR
Tumor Cell Biology Training Program
$480,906Gay Miriam Crooks · University Of California Los Angeles · T32 · FY2023 · CA
Evaluation and Treatment of Skeletal Muscle Weakness in Critically Ill Patients
$480,899Gerald S. Supinski · University Of Kentucky · RC1 · FY2009 · HL
Mucus Obstructed Mice for Biomarker and Drug Development
$480,885Richard C Boucher · Univ Of North Carolina Chapel Hill · P01 · FY2015 · HL
Maximizing the predictive power of high-throughput, microscopy-based phenotypic screens
$480,849Lani F Wu · University Of California, San Francisco · R01 · FY2020 · CA
Maintenance of Animal Models of Human Hemophilia and VWD
$480,792Timothy Charles Nichols · Univ Of North Carolina Chapel Hill · R24 · FY2013 · HL
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
$480,738Michael J Eck · Dana-Farber Cancer Inst · R01 · FY2022 · CA